Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Imaging and dosimetry for alpha-particle emitter radiopharmaceutical therapy: improving radiopharmaceutical therapy by looking into the black box.

Literature DB >> 34782911

Imaging and dosimetry for alpha-particle emitter radiopharmaceutical therapy: improving radiopharmaceutical therapy by looking into the black box.

George Sgouros¹, Eric Frey², Yong Du², Rob Hobbs², Wesley Bolch².

Abstract

Radiopharmaceutical therapy using α-particle emitting radionuclides (αRPT) is a novel treatment modality that delivers highly potent alpha-particles to cancer cells or their environment. We review the advantages and challenges of imaging and dosimetry in implementing αRPT for cancer patients.

Entities: Chemical

Keywords: Alpha-particle emitter; Black box; Dosimetry; Radiopharmaceutical therapeutics

Mesh：

Substances：

Year: 2021 PMID： 34782911 DOI： 10.1007/s00259-021-05583-x

Source DB: PubMed Journal: Eur J Nucl Med Mol Imaging ISSN： 1619-7070 Impact factor: 9.236

Keyword Cloud
References

66 in total

1. Tumor-Absorbed Dose Predicts Progression-Free Survival Following (131)I-Tositumomab Radioimmunotherapy.

Authors: Yuni K Dewaraja; Matthew J Schipper; Jincheng Shen; Lauren B Smith; Jure Murgic; Hatice Savas; Ehab Youssef; Denise Regan; Scott J Wilderman; Peter L Roberson; Mark S Kaminski; Anca M Avram
Journal: J Nucl Med Date: 2014-05-19 Impact factor: 10.057

2. α-Particle-Emitter Radiopharmaceutical Therapy: Resistance Is Futile.

Authors: George Sgouros
Journal: Cancer Res Date: 2019-11-01 Impact factor: 12.701

Review 3. Correlation of dose with toxicity and tumour response to ⁹⁰Y- and ¹⁷⁷Lu-PRRT provides the basis for optimization through individualized treatment planning.

Authors: Marta Cremonesi; Mahila Esmeralda Ferrari; Lisa Bodei; Carlo Chiesa; Anna Sarnelli; Cristina Garibaldi; Massimiliano Pacilio; Lidia Strigari; Paul Eugene Summers; Roberto Orecchia; Chiara Maria Grana; Francesca Botta
Journal: Eur J Nucl Med Mol Imaging Date: 2018-05-21 Impact factor: 9.236

4. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment.

Authors: Mattias Sandström; Ulrike Garske-Román; Dan Granberg; Silvia Johansson; Charles Widström; Barbro Eriksson; Anders Sundin; Hans Lundqvist; Mark Lubberink
Journal: J Nucl Med Date: 2012-12-07 Impact factor: 10.057

Review 5. Dosimetry, Radiobiology and Synthetic Lethality: Radiopharmaceutical Therapy (RPT) With Alpha-Particle-Emitters.

Authors: George Sgouros
Journal: Semin Nucl Med Date: 2020-02-26 Impact factor: 4.446

6. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.

Authors: Valérie Vilgrain; Helena Pereira; Eric Assenat; Boris Guiu; Alina Diana Ilonca; Georges-Philippe Pageaux; Annie Sibert; Mohamed Bouattour; Rachida Lebtahi; Wassim Allaham; Hélène Barraud; Valérie Laurent; Elodie Mathias; Jean-Pierre Bronowicki; Jean-Pierre Tasu; Rémy Perdrisot; Christine Silvain; René Gerolami; Olivier Mundler; Jean-Francois Seitz; Vincent Vidal; Christophe Aubé; Frédéric Oberti; Olivier Couturier; Isabelle Brenot-Rossi; Jean-Luc Raoul; Anthony Sarran; Charlotte Costentin; Emmanuel Itti; Alain Luciani; René Adam; Maïté Lewin; Didier Samuel; Maxime Ronot; Aurelia Dinut; Laurent Castera; Gilles Chatellier
Journal: Lancet Oncol Date: 2017-10-26 Impact factor: 41.316

7. Dosimetry of ¹⁷⁷Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes.

Authors: John Violet; Price Jackson; Justin Ferdinandus; Shahneen Sandhu; Tim Akhurst; Amir Iravani; Grace Kong; Aravind Ravi Kumar; Sue Ping Thang; Peter Eu; Mark Scalzo; Declan Murphy; Scott Williams; Rodney J Hicks; Michael S Hofman
Journal: J Nucl Med Date: 2018-10-05 Impact factor: 10.057

8. Individualised ¹⁷⁷Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry.

Authors: Anna Sundlöv; Katarina Sjögreen-Gleisner; Johanna Svensson; Michael Ljungberg; Tomas Olsson; Peter Bernhardt; Jan Tennvall
Journal: Eur J Nucl Med Mol Imaging Date: 2017-03-22 Impact factor: 9.236

9. Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force.

Authors: Caroline Stokke; Pablo Minguez Gabiña; Pavel Solný; Francesco Cicone; Mattias Sandström; Katarina Sjögreen Gleisner; Carlo Chiesa; Emiliano Spezi; Maria Paphiti; Mark Konijnenberg; Matt Aldridge; Jill Tipping; Michael Wissmeyer; Boudewijn Brans; Klaus Bacher; Carsten Kobe; Glenn Flux
Journal: EJNMMI Phys Date: 2017-11-21

Review 10. Radiopharmaceutical therapy in cancer: clinical advances and challenges.

Authors: George Sgouros; Lisa Bodei; Michael R McDevitt; Jessie R Nedrow
Journal: Nat Rev Drug Discov Date: 2020-07-29 Impact factor: 84.694

Review 3. Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning.

Review 5. Dosimetry, Radiobiology and Synthetic Lethality: Radiopharmaceutical Therapy (RPT) With Alpha-Particle-Emitters.

Review 10. Radiopharmaceutical therapy in cancer: clinical advances and challenges.

Review 3. Correlation of dose with toxicity and tumour response to ⁹⁰Y- and ¹⁷⁷Lu-PRRT provides the basis for optimization through individualized treatment planning.